Literature DB >> 1848677

Neuronal inclusions of Parkinson's disease.

W R Gibb1, T Scott, A J Lees.   

Abstract

Two distinct neuronal inclusions occur in Parkinson's disease. The Lewy body is the diagnostic hallmark and is recognized by its eosinophilic body and unstained halo. It can be found in specific regions of the nervous system, where its frequency, size, shape, and structure differ. Large neurons of the dorsal vagal nucleus and sympathetic ganglia often contain particularly large quantities of Lewy-body-like matter. It consists of filament in the outer part and electron dense material in the core, the outer part staining with silver and with antibodies to neurofilament and tubulin. The pale body is restricted to the substantia nigra and locus ceruleus. It does not react with conventional stains, silver, or neurofilament antibodies, and has a homogeneous structure with a granular and vesicular surface texture. It contains sparse granular matter, vacuoles, and filaments, surrounded by melanin. The Lewy body and pale body may be juxtaposed or contiguous in some cells, but their distinct appearances and structures indicate that they are separate inclusions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1848677     DOI: 10.1002/mds.870060103

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  18 in total

Review 1.  Estrogens and Parkinson disease: neuroprotective, symptomatic, neither, or both?

Authors:  Rachel Saunders-Pullman
Journal:  Endocrine       Date:  2003-06       Impact factor: 3.633

Review 2.  The Lewy body in Parkinson's disease and related neurodegenerative disorders.

Authors:  Koichi Wakabayashi; Kunikazu Tanji; Saori Odagiri; Yasuo Miki; Fumiaki Mori; Hitoshi Takahashi
Journal:  Mol Neurobiol       Date:  2012-05-24       Impact factor: 5.590

Review 3.  Pattern of brain destruction in Parkinson's and Alzheimer's diseases.

Authors:  H Braak; E Braak; D Yilmazer; R A de Vos; E N Jansen; J Bohl
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  A specific clinical pattern of camptocormia in Parkinson's disease.

Authors:  A-C Lepoutre; D Devos; A Blanchard-Dauphin; V Pardessus; C-A Maurage; D Ferriby; J-F Hurtevent; A Cotten; A Destée; L Defebvre
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-05-30       Impact factor: 10.154

Review 5.  The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease.

Authors:  Noémie Cresto; Camille Gardier; Francesco Gubinelli; Marie-Claude Gaillard; Géraldine Liot; Andrew B West; Emmanuel Brouillet
Journal:  Eur J Neurosci       Date:  2018-10-24       Impact factor: 3.386

Review 6.  Potential Pathways of Abnormal Tau and α-Synuclein Dissemination in Sporadic Alzheimer's and Parkinson's Diseases.

Authors:  Heiko Braak; Kelly Del Tredici
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-11-01       Impact factor: 10.005

Review 7.  Reverse engineering Lewy bodies: how far have we come and how far can we go?

Authors:  Mohamed Bilal Fares; Somanath Jagannath; Hilal A Lashuel
Journal:  Nat Rev Neurosci       Date:  2021-01-11       Impact factor: 34.870

8.  An early cytoplasmic change before Lewy body maturation: an ultrastructural study of the substantia nigra from an autopsy case of juvenile parkinsonism.

Authors:  K Hayashida; S Oyanagi; Y Mizutani; M Yokochi
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

9.  Impaired gastric myoelectrical activity in patients with Parkinson's disease and effect of levodopa treatment.

Authors:  Ching-Liang Lu; Din-E Shan; Chih-Yen Chen; Jiing-Chyuan Luo; Full-Young Chang; Shou-Dong Lee; Han-Chang Wu; J D Z Chen
Journal:  Dig Dis Sci       Date:  2004-05       Impact factor: 3.199

10.  Ogg1 null mice exhibit age-associated loss of the nigrostriatal pathway and increased sensitivity to MPTP.

Authors:  Fernando Cardozo-Pelaez; Monica Sanchez-Contreras; Andrew B C Nevin
Journal:  Neurochem Int       Date:  2012-06-26       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.